Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$7.5 million.

  • Ironwood Pharmaceuticals' Non Operating Income rose 971.33% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year decrease of 710.08%. This contributed to the annual value of -$27.9 million for FY2024, which is 12990.13% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Non Operating Income stood at -$7.5 million for Q3 2025, which was up 971.33% from -$7.5 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Non Operating Income registered a high of $6.9 million during Q2 2023, and its lowest value of -$10.7 million during Q2 2021.
  • For the 5-year period, Ironwood Pharmaceuticals' Non Operating Income averaged around -$4.3 million, with its median value being -$6.1 million (2024).
  • Over the last 5 years, Ironwood Pharmaceuticals' Non Operating Income had its largest YoY gain of 51737.87% in 2023, and its largest YoY loss of 66422.59% in 2023.
  • Ironwood Pharmaceuticals' Non Operating Income (Quarter) stood at -$10.3 million in 2021, then skyrocketed by 137.75% to $3.9 million in 2022, then crashed by 285.26% to -$7.2 million in 2023, then fell by 3.69% to -$7.5 million in 2024, then grew by 0.43% to -$7.5 million in 2025.
  • Its last three reported values are -$7.5 million in Q3 2025, -$7.5 million for Q2 2025, and -$7.2 million during Q1 2025.